Open AccessInfluence of Tamoxifen‐Medroxyprogesterone Sequential Therapy on Estrogen and Progesterone Receptor Contents of Breast Cancer
Author(s) -
Noguchi Shinzaburo,
Yamamoto Hitoshi,
Inaji Hideo,
Imaoka Shingi,
Koyama Hiroki
Publication year - 1989
Publication title -
japanese journal of cancer research
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 2.035
H-Index - 141
eISSN - 1349-7006
pISSN - 0910-5050
DOI - 10.1111/j.1349-7006.1989.tb02300.x
Subject(s) - medroxyprogesterone acetate , medroxyprogesterone , tamoxifen , medicine , breast cancer , progesterone receptor , estrogen , endocrinology , estrogen receptor , antiestrogen , mammary gland , gynecology , cancer , urology
The influence of tamoxifen (TAM) and medroxyprogesterone acetate (MPA) sequential administration on the estrogen receptor (ER) and progesterone receptor (PR) contents of breast cancer was studied in 68 patients with operable breast cancer. TAM was used as a primer of PR induction in order to enhance the effects of MPA. Half of the patients (n=34) were preoperatively treated with TAM (20 nig/day for 7 days) and sequentially with MPA (1200 mg/day for 17 (median) days). ER and PR of surgical specimens were assayed by enzyme immunoassay and the results were compared with those obtained from the other half of the patients (n=34), who had not received any treatment before surgery. TAM‐MPA treatment significantly lowered PR in the cytosol regardless of the menopausal status. On the other hand, TAM‐MPA treatment significantly lowered ER in the cytosol only in the postmenopausals but not in the premenopansals. These results demonstrate that reduction of ER provoked by TAM‐MPA treatment is dependent on menopausal status.